Pneumococcal Polysaccharide Vaccine (ppsv23) - Epidemiology

Relevant Publications

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.

Issue Release: 2024

Antimicrobial Resistance of Clinical Serotypes between 2017 and 2022 in Crete, Greece.

Issue Release: 2024

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.

Issue Release: 2024

Strategies for pneumococcal vaccination in older adults in the coming era.

Issue Release: 2024

No Waning of Pneumococcal Vaccine Responses over Time in People with Inflammatory Arthritis: Findings from a Single Centre Cohort.

Issue Release: 2024

Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults: a population-based cohort study.

Issue Release: 2024

Pneumococcal vaccination strategies in 50-year-olds to decrease racial disparities: a US societal perspective cost-effectiveness analysis.

Issue Release: 2024

Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.

Issue Release: 2024

Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population.

Issue Release: 2024

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older.

Issue Release: 2024

The Effectiveness of 23-valent Pneumococcal Polysaccharide Vaccine on Elderly Colorectal Cancer Long-Term Survivors: A population-based exact-matched cohort study.

Issue Release: 2024

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.

Issue Release: 2024

A randomized, triple-blinded, placebo-controlled clinical trial evaluating immune responses of Typhim Vi and PPSV23 vaccines in healthy adults: The PREP study.

Issue Release: 2024

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.

Issue Release: 2024

Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults.

Issue Release: 2024

Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine.

Issue Release: 2024

Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.

Issue Release: 2024

Improving Pneumococcal Vaccination Rates in Immunosuppressed Pediatric Patients with Rheumatic Disease.

Issue Release: 2024

Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.

Issue Release: 2024

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan.

Issue Release: 2024

What are Outcomes in Epidemiology?

What Challenges are Faced in Quality Improvement Initiatives?

What role does cost-effectiveness analysis play in epidemiology?

How Do Socioeconomic Factors Influence Pneumonia Rates?

What are Health Behaviors?

What are the Standards and Regulations for Packaging in Epidemiology?

What is Psychotherapy?

How to Interpret a Covariance Matrix?

How Can the Amplification Effect be Mitigated?

What is the Importance of Systematic Reviews?

Pneumococcal Polysaccharide Vaccine (ppsv23) - Epidemiology

Relevant Publications

Partnered Content Networks

Relevant Topics